Common polymorphism in the cannabinoid type 1 receptor gene (CNR1) is associated with microvascular complications in type 2 diabetes.

[1]  H. Flynn,et al.  Genetics and diabetic retinopathy. , 2012, Current diabetes reviews.

[2]  A. McAinch,et al.  Endocannabinoids and the renal proximal tubule: an emerging role in diabetic nephropathy. , 2012, The international journal of biochemistry & cell biology.

[3]  E. Ntzani,et al.  Genetic risk factors for type 2 diabetes: insights from the emerging genomic evidence. , 2012, Current vascular pharmacology.

[4]  D. Petrovič,et al.  GSTT1 Null Genotype Is a Risk Factor for Diabetic Retinopathy in Caucasians with Type 2 Diabetes, whereas GSTM1 Null Genotype Might Confer Protection against Retinopathy , 2012, Disease markers.

[5]  K. Mackie,et al.  Cannabinoid 1 Receptor Promotes Cardiac Dysfunction, Oxidative Stress, Inflammation, and Fibrosis in Diabetic Cardiomyopathy , 2012, Diabetes.

[6]  R. González-Sarmiento,et al.  Cannabinoid receptor 1 gene is associated with alcohol dependence. , 2012, Alcoholism, clinical and experimental research.

[7]  B. Cravatt,et al.  Hyperglycemia induces apoptosis via CB1 activation through the decrease of FAAH 1 in retianl pigment epithelial cells , 2012, Journal of cellular physiology.

[8]  P. Pacher,et al.  The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. , 2012, The American journal of pathology.

[9]  Wenchao Hu,et al.  G1359A Polymorphism in the Cannabinoid Receptor-1 Gene is Associated With the Presence of Coronary Artery Disease in Patients With Type 2 Diabetes , 2012, Journal of Investigative Medicine.

[10]  Barry I Freedman,et al.  Genetic and environmental factors associated with type 2 diabetes and diabetic vascular complications. , 2012, The review of diabetic studies : RDS.

[11]  S. Hadjadj,et al.  Allelic variations in superoxide dismutase-1 (SOD1) gene are associated with increased risk of diabetic nephropathy in type 1 diabetic subjects. , 2011, Molecular genetics and metabolism.

[12]  C. Fox,et al.  Variants at the Endocannabinoid Receptor CB1 Gene (CNR1) and Insulin Sensitivity, Type 2 Diabetes, and Coronary Heart Disease , 2011, Obesity.

[13]  D. Petrovic,et al.  A review of oxidative stress related genes and new antioxidant therapy in diabetic nephropathy. , 2011, Cardiovascular & hematological agents in medicinal chemistry.

[14]  P. Franks.  Gene × Environment Interactions in Type 2 Diabetes , 2011, Current diabetes reports.

[15]  L. Devi,et al.  The Highs and Lows of Cannabinoid Receptor Expression in Disease: Mechanisms and Their Therapeutic Implications , 2011, Pharmacological Reviews.

[16]  D. D. de Luis,et al.  Relation of G1359A polymorphism of the cannabinoid receptor (CB1) gene with metabolic syndrome by ATP III classification , 2011, Diabetes/metabolism research and reviews.

[17]  P. Pacher,et al.  Cannabinoid 1 receptor activation contributes to vascular inflammation and cell death in a mouse model of diabetic retinopathy and a human retinal cell line , 2011, Diabetologia.

[18]  A. Vasku,et al.  A common variation in the cannabinoid 1 receptor (CNR1) gene is associated with pre-eclampsia in the Central European population. , 2011, European journal of obstetrics, gynecology, and reproductive biology.

[19]  J. Petrie,et al.  Implications of genome wide association studies for the understanding of type 2 diabetes pathophysiology. , 2011, Biochemical pharmacology.

[20]  Yanjun Zhang,et al.  G1359A polymorphism in the cannabinoid receptor-1 gene is associated with coronary artery disease in the Chinese Han population. , 2011, Clinical laboratory.

[21]  S. Maeda,et al.  Genetics of type 2 diabetes: the GWAS era and future perspectives [Review]. , 2011, Endocrine journal.

[22]  S. K. Lim,et al.  Cannabinoid receptor 1 mediates palmitic acid‐induced apoptosis via endoplasmic reticulum stress in human renal proximal tubular cells , 2010, Journal of cellular physiology.

[23]  Wenchao Hu,et al.  G1359A polymorphism in the cannabinoid receptor-1 gene is associated with metabolic syndrome in the Chinese Han population. , 2010, Archives of medical research.

[24]  A. Howlett,et al.  CB(1) cannabinoid receptors and their associated proteins. , 2010, Current medicinal chemistry.

[25]  S. Brand,et al.  The Cannabinoid 1 Receptor (CNR1) 1359 G/A Polymorphism Modulates Susceptibility to Ulcerative Colitis and the Phenotype in Crohn's Disease , 2010, PloS one.

[26]  M. Rastaldi,et al.  Cannabinoid Receptor 1 Blockade Ameliorates Albuminuria in Experimental Diabetic Nephropathy , 2010, Diabetes.

[27]  S. Steffens,et al.  The emerging role of the endocannabinoid system in cardiovascular disease , 2009, Seminars in Immunopathology.

[28]  T. Hansen,et al.  Endocannabinoid receptor 1 gene variations increase risk for obesity and modulate body mass index in European populations. , 2008, Human molecular genetics.

[29]  J. Herbert,et al.  Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats. , 2007, Kidney international.

[30]  T. Frayling.  Genome–wide association studies provide new insights into type 2 diabetes aetiology , 2007, Nature Reviews Genetics.

[31]  D. Tregouet,et al.  Genetic variations at the endocannabinoid type 1 receptor gene (CNR1) are associated with obesity phenotypes in men. , 2007, The Journal of clinical endocrinology and metabolism.

[32]  I. Matias,et al.  Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration. , 2006, Prostaglandins, leukotrienes, and essential fatty acids.

[33]  Y. Khalifa,et al.  Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. , 2005, The American journal of pathology.

[34]  B. Peterlin,et al.  Aldose reductase (AC)n gene polymorphism and susceptibility to diabetic retinopathy in Type 2 diabetes in Caucasians. , 2005, Journal of diabetes and its complications.

[35]  G. Uhl,et al.  Human cannabinoid receptor 1: 5′ exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse , 2004, Molecular Psychiatry.